TCM
CYTO

Tekla Capital Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Tekla Capital Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed -$457K – 193
2017
Q4 		$457K Hold
10
– – 0.02% 153
2017
Q3 		$635K Hold
10
– – 0.02% 142
2017
Q2 		$554K Hold
10
– – 0.02% 137
2017
Q1 		$712K Hold
10
– – 0.03% 131
2016
Q4 		$829K Hold
10
– – 0.04% 132
2016
Q3 		$1.34M Hold
10
– – 0.05% 128
2016
Q2 		$3.5M Hold
10
– – 0.14% 109
2016
Q1 		$3.04M Sell
10
-6
-38% -$2.14M 0.13% 102
2015
Q4 		$6.2M Sell
16
-10
-38% -$2.88M 0.22% 82
2015
Q3 		$7.5M Hold
26
– – 0.27% 82
2015
Q2 		$10.4M Buy
+26
New +$10.8M 0.38% 60

Other funds holding CYTO

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tekla Capital Management's CYTO Position: Q1 2018 in Review

Tekla Capital Management sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2018, closing a stake of 10 shares — an estimated $457K sold.

Tekla Capital Management first reported a position in CYTO in Q2 2015 and held it in 11 quarters. The position peaked at $10.4M in Q2 2015. 8 funds tracked by Wall St. Rank hold CYTO as of Q1 2018.

  • Tekla Capital Management reported no remaining Altamira Therapeutics Ltd position as of Q1 2018 after selling out during the quarter.
  • Tekla Capital Management sold 10 Altamira Therapeutics Ltd shares in Q1 2018, an estimated $457K.
  • Tekla Capital Management first reported a position in Altamira Therapeutics Ltd in Q2 2015 and held it in 11 quarters.
  • Tekla Capital Management's Altamira Therapeutics Ltd position peaked at $10.4M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2018.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.